Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Bibliografski detalji
Glavni autori:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Format:	Članak
Jezik:	English
Izdano:	Elsevier 2020-10-01
Serija:	World Allergy Organization Journal
Teme:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Online pristup:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Slični predmeti

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
od: Claudia Crimi, i dr.
Izdano: (2023-11-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
od: Carla Rognoni, i dr.
Izdano: (2023-06-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
od: Paolo Solidoro, i dr.
Izdano: (2022-01-01)

Critical evaluation of asthma biomarkers in clinical practice
od: Giuseppe Guida, i dr.
Izdano: (2022-10-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
od: Giorgio Walter Canonica, i dr.
Izdano: (2020-08-01)

Asthma severity: the patient’s point of view
od: Gabriella Guarnieri, i dr.
Izdano: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
od: Giovanna Elisiana Carpagnano, i dr.
Izdano: (2023-10-01)

Severe asthma: One disease and multiple definitions
od: Diego Bagnasco, MD, PhD, i dr.
Izdano: (2021-11-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
od: Diego Bagnasco, i dr.
Izdano: (2023-08-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
od: Marco Caminati, MD, i dr.
Izdano: (2024-08-01)

Phenotype overlap in the natural history of asthma
od: Fabio L.M. Ricciardolo, i dr.
Izdano: (2023-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
od: Paolo Solidoro, i dr.
Izdano: (2019-04-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
od: Alessandra Vultaggio, i dr.
Izdano: (2023-05-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
od: Giorgio Walter Canonica, i dr.
Izdano: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
od: Giorgio Walter Canonica, MD, i dr.
Izdano: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
od: Francesco Menzella, i dr.
Izdano: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
od: Alberto Papi, i dr.
Izdano: (2020-08-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
od: Maria D'Amato, i dr.
Izdano: (2022-05-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
od: Giulia Scioscia, i dr.
Izdano: (2020-03-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
od: Corrado Pelaia, i dr.
Izdano: (2023-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
od: Diego Bagnasco, i dr.
Izdano: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
od: Dejan Radovanovic, i dr.
Izdano: (2017-05-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
od: Francesca Bertolini, i dr.
Izdano: (2025-02-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
od: Erminia Ridolo, i dr.
Izdano: (2020-10-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
od: Dejan Radovanovic, i dr.
Izdano: (2017-06-01)

Is it severe asthma or asthma with severe comorbidities?
od: Brussino L, i dr.
Izdano: (2017-11-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
od: Giovanna Elisiana Carpagnano, i dr.
Izdano: (2021-03-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
od: Carlo Lombardi, i dr.
Izdano: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
od: F.G. Salerno, i dr.
Izdano: (2016-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
od: Carlo Lombardi, i dr.
Izdano: (2024-07-01)

Alexithymia and asthma: a systematic review
od: Orlando Silvestro, i dr.
Izdano: (2023-08-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
od: Corrado Pelaia, i dr.
Izdano: (2019-12-01)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
od: Carpagnano GE, i dr.
Izdano: (2019-03-01)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
od: Giorgio Walter Canonica, i dr.
Izdano: (2018-11-01)

Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis
od: Filippo Rumi, i dr.
Izdano: (2022-04-01)

Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
od: Francesco Menzella, i dr.
Izdano: (2022-11-01)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
od: Cristiano Caruso, i dr.
Izdano: (2022-09-01)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
od: Andrea Portacci, i dr.
Izdano: (2023-10-01)

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
od: Andrea Giovanni Ledda, i dr.
Izdano: (2023-09-01)

Dupilumab in the Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma—A Multidisciplinary Monocentric Real-Life Study
od: Gian Luca Fadda, i dr.
Izdano: (2025-02-01)